NRX Pharmaceuticals, Inc. (NRXP)
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
NRx Pharmaceuticals, Inc.
NASDAQ:NRXPHealthcare · Biotechnology
AHAfter hours+0.38%$2.39
Prev close$2.380.00%Close$2.38+0.38%Now$2.39
Close$2.38+0.00%
Mkt Cap$103.04M
Float41.51M
O/S43.3M
VOL877K sh
$ Vol$2.09M
RVOL0.51×
Inst Own28.1%
SI24.0%
Dilution
Financials Summary
Revenue$1.23M
Net Income-$28.62M
Total Assets$12.96M
Free Cash Flow-$14.11M
Debt & Equity
Total Debt$631K
Total Equity-$15.94M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:10Reverse splitApr 2, 202410 shares → 1
Balance Sheet Details
Assets$12.96M
Liabilities$28.89M
Accounts Receivable$161K
Accounts Payable$4.27M
Inventory$0
PP&E (Net)$633K
Goodwill$1.79M
Intangible Assets$925K
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Revenue | $1.23M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $505K | $5K | $5K | $4K | $2K | $2K | $0 | $1.01M | $0 |
| Gross Profit | $720K | -$5K | -$5K | -$4K | -$2K | -$2K | $0 | -$1.01M | $0 |
| Gross Margin | 58.8% | - | - | - | - | - | - | - | - |
| Research and Development | $3.78M | $6.2M | $13.37M | $17.03M | $20.26M | $10.63M | $0 | $0 | $0 |
| Selling, General, and Administrative | $13.06M | $13.5M | $14.21M | $27.3M | $74.94M | $11.43M | $713K | $1.01M | $0 |
| Other | $106K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $16.94M | $19.7M | $27.58M | $44.33M | $95.2M | $22.06M | $713K | $0 | $0 |
| Operating Income (EBIT) | -$16.22M | -$19.7M | -$27.59M | -$44.34M | -$95.2M | -$22.06M | -$713K | -$1.01M | $0 |
| Operating Margin | -1324.4% | - | - | - | - | - | - | - | - |
| Interest Expense | $671K | $1.08M | $120K | $0 | $18K | $56K | $0 | $0 | $0 |
| Interest Income | $12K | $44K | $494K | $249K | $18 | $56 | $1.21M | $1.09M | $0 |
| Other Income (Expense) | -$12.4M | -$5.42M | -$2.56M | $4.58M | $2.14M | -$29.72M | $1.21M | $1.09M | -$105K |
| Income Before Tax (EBT) | -$28.62M | -$25.13M | -$30.15M | -$39.75M | -$93.06M | -$51.78M | $493K | $82K | -$105K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $84K | $16K | $0 |
| Net Income | -$28.62M | -$25.13M | -$30.15M | -$39.75M | -$93.06M | -$51.78M | $408K | $66K | -$105K |
| Net Income Margin | -2336.5% | - | - | - | - | - | - | - | - |
| Supplementary Data | |||||||||
| EPS | -1.34 | -2.39 | -3.98 | -0.60 | -7.44 | -1.51 | 0.80 | 0.07 | -0.12 |
| Diluted EPS | -1.34 | -2.39 | -3.98 | -0.60 | -7.44 | -1.51 | 0.80 | 0.07 | -0.12 |
| Weighted Average OS | 21.40M | 10.52M | 7.58M | 65.77M | 46.92M | 546,586 | 508,835 | 892,496 | 903,550 |
| EBITDA | -$27.81M | -$24.04M | -$30.02M | -$39.75M | -$93.04M | -$51.72M | $493K | $82K | -$105K |
| EBITDA Margin | -2270.0% | - | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $7.8M | $1.44M | $4.59M | $20.05M | $27.61M | $1.86M | $6 | $11K | $449K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $7.8M | $1.44M | $4.59M | $20.05M | $27.61M | $1.86M | $6 | $11K | $449K |
| Accounts Receivable | $161K | $0 | $6K | $7K | $0 | $831K | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $214K | $0 | $0 | $0 |
| Other Current Assets | $0 | $0 | $0 | $0 | $0 | $26K | $0 | $19K | $87K |
| Total Current Assets | $8.89M | $3.3M | $6.88M | $25.8M | $32.71M | $2.93M | $69K | $30K | $536K |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $633K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.79M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $925K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $397K | $0 | $0 | $0 | $0 | $0 | $32.01M | $70.77M | $69.03M |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $316K | $349K | $431K | $21K | $15K | $11K | $0 | $0 | $0 |
| Total Long-Term Assets | $4.06M | $349K | $431K | $21K | $15K | $11K | $32.01M | $70.77M | $69.03M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $12.96M | $3.65M | $7.32M | $25.82M | $32.73M | $2.94M | $32.07M | $70.8M | $69.57M |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $4.27M | $4.13M | $4.63M | $2.08M | $3.69M | $3.15M | $0 | $551K | $86K |
| Short-Term Debt | $0 | $1.57M | $9.16M | $7.7M | $518K | $249K | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $52K | $0 | $16K | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $18.31M | $10.93M | $4.42M | $37K | $4.87M | $0 | $622K | $0 | $8K |
| Total Current Liabilities | $28.58M | $21.86M | $19.05M | $15.59M | $11.92M | $46.16M | $622K | $567K | $93K |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $0 | $5.01M | $0 | $2.82M | $0 | $548K | $1.95M | $690K | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $315K | $5.01M | $0 | $2.82M | $0 | $548K | $1.95M | $690K | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $28.89M | $26.87M | $19.05M | $18.41M | $11.92M | $46.71M | $2.57M | $1.26M | $93K |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $3K | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $32K | $15K | $84K | $67K | $59K | $43K | $24.5M | $64.54M | $64.48M |
| Retained Earnings | -$306.89M | -$278.27M | -$253.15M | -$223M | -$183.24M | -$90.18M | $369K | -$39K | -$105K |
| Comprehensive Income & Other | $0 | $0 | -$3K | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $290.93M | $255.03M | $241.33M | $230.34M | $203.99M | $46.37M | $4.63M | $5.04M | $5.1M |
| Total Equity | -$15.94M | -$23.22M | -$11.73M | $7.41M | $20.81M | -$43.77M | $29.5M | $69.54M | $69.47M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $12.96M | $3.65M | $7.32M | $25.82M | $32.73M | $2.94M | $32.07M | $70.8M | $69.57M |
| Supplementary Data | |||||||||
| Total Debt | $631K | $6.58M | $9.16M | $10.53M | $518K | $797K | $1.95M | $690K | $0 |
| Net Debt | -$7.17M | $5.13M | $4.57M | -$9.53M | -$27.09M | -$1.06M | $1.95M | $679K | -$449K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Operating Activities | |||||||||
| Net Income | -$28.62M | -$25.13M | -$30.15M | -$39.75M | -$93.06M | -$51.78M | $408K | $66K | -$105K |
| Depreciation & Amortization | $143K | $5K | $5K | $4K | $2K | $2K | $0 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $228K | $486K | $387K | $0 | $7.79M | $730K | $0 | $0 | $0 |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | $48K | $0 | $0 | $0 | $831K | -$831K | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $113K | -$5.22M | $2.65M | $0 | -$19K | $1.18M | $0 | $465K | $86K |
| Other Working Capital | $1.25M | $10.51M | $2.51M | $699K | -$5.71M | $3.1M | $5K | $84K | -$87K |
| Total Working Capital Change | $1.41M | $5.29M | $5.16M | $699K | -$4.9M | $3.45M | $5K | $550K | -$1K |
| Other Non-Cash Items | $12.73M | $8.71M | $2.94M | -$704K | $52.47M | $45.33M | -$1.21M | -$1.55M | -$115K |
| Net Cash from Operating | -$14.11M | -$10.64M | -$21.66M | -$39.76M | -$37.7M | -$2.27M | -$793K | -$473K | -$136K |
| Investing Activities | |||||||||
| Capital Expenditures | $0 | $0 | -$3K | $0 | -$7K | -$2K | $0 | $0 | $0 |
| Acquisitions | -$2.38M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$432K | $0 | $0 | -$10K | $0 | $0 | -$993K | -$690K | -$69M |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $41.24M | $42K | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$648K | -$69M |
| Net Cash from Investing | -$2.81M | $0 | -$3K | -$10K | -$7K | -$2K | $40.25M | -$648K | -$69M |
| Financing Activities | |||||||||
| Debt Repaid | -$4.68M | $1.5M | $3.09M | -$10.02M | - | -$620K | -$1.26M | -$690K | - |
| Common Stock Issuance | $18.95M | $5.91M | $8.12M | $22.71M | $54.78M | $2.58M | $0 | -$8K | $69.59M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | -$40.73M | $0 | $70.03M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$350K | $3.07M | $0 | $0 | $9.95M | $0 | $0 | $0 | $0 |
| Net Cash from Financing | $23.28M | $7.49M | $6.2M | $32.21M | $63.46M | $3.25M | -$39.46M | $683K | $69.59M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $6.35M | -$3.15M | -$15.46M | -$7.55M | $25.75M | $982K | -$11K | -$438K | $449K |
| Supplementary Data | |||||||||
| Operating Cash Flow | -$14.11M | -$10.64M | -$21.66M | -$39.76M | -$37.7M | -$2.27M | -$793K | -$473K | -$136K |
| Capital Expenditure | $0 | $0 | -$3K | $0 | -$7K | -$2K | $1 | $0 | $0 |
| Free Cash Flow | -$14.11M | -$10.64M | -$21.66M | -$39.76M | -$37.71M | -$2.27M | -$793K | -$473K | -$136K |
| Cash at Beginning | $1.44M | $4.59M | $20.05M | $27.61M | $1.86M | $877K | $11K | $449K | $0 |
| Cash at End | $7.8M | $1.44M | $4.59M | $20.05M | $27.61M | $1.86M | $6 | $11K | $449K |